热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　野村发布研报称，将中国生物制药（01177）目标价由6.42港元降至5.52港元，评级“买入”。该行称，中生制药去年业绩不如预期，而完成了数个附属公司的出售应可令2025年的财务表现更一致及可比，今年增长指引达两位数。

　　报告指，公司去年下半年收入同比增9%，经常性盈利同比增55%。以板块划分，去年下半年肿瘤科药物、止痛药以及呼吸道药物分别录得销售53.7亿元人民币、18.7亿元人民币以及13.7亿元人民币，同比增24.5%、6.5%及7.3%，而肝炎药物销售同比跌8.4%至14.1亿元人民币。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.